Jiangsu Kangyuan Meiyu Biopharmaceutical

Jiangsu Kangyuan Meiyu Biopharmaceutical is a Chinese biotechnology company and a subsidiary of the prominent Jiangsu Kanion Pharmaceutical group. The company focuses on the research and development of innovative biological drugs and high-end chemical medicines, particularly in the fields of metabolic diseases and oncology. Leveraging the resources of its parent group, Kangyuan Meiyu operates advanced R&D facilities to advance its pipeline of recombinant proteins and monoclonal antibodies. Its portfolio includes promising candidates for the treatment of type 2 diabetes and various solid tumors, aiming to bridge the gap between traditional Chinese medicine expertise and modern biopharmaceutical innovation.